The New Era of Drug Repurposing: Turning Forgotten Medicines into Lifelines
For decades, the pharmaceutical industry has followed a linear path: identify a target, develop a new molecule, and spend billions on clinical trials to prove its safety. However, a shift is occurring toward drug repurposing—the process of finding new therapeutic uses for existing, approved medications.
The recent breakthrough in treating Bachmann-Bupp syndrome (BABS) using eflornithine, a drug originally designed for West African sleeping sickness, exemplifies this trend. By targeting a specific biological mechanism rather than a specific disease, researchers are unlocking treatments for patients who previously had no options.
This approach significantly reduces the time and cost associated with drug development. Because the safety profiles of these drugs are already established, clinicians can move more quickly from diagnosis to treatment. In the case of BABS, the transition from diagnosis to treatment took just 16 months for one patient.
Drug repurposing isn’t just for rare diseases. Many common medications, including certain antidepressants and blood pressure drugs, were discovered to treat entirely different conditions through similar “off-label” observation, and research.
Precision Medicine: Moving Beyond the General Diagnosis
The future of rare disease treatment lies in precision medicine—treating the patient based on their specific genetic makeup rather than a broad disease label. The BABS study highlights a critical nuance: not every patient with a genetic mutation will respond to the same drug.
Researchers discovered that eflornithine works by blocking an overactive enzyme called ornithine decarboxylase. However, some patients with ODC1 gene changes do not show the same increase in enzyme activity. This means the drug may not be a “one size fits all” solution, even within a single syndrome.
Future trends suggest a move toward mechanism-based prescribing
. Instead of asking, Does this drug treat BABS?
doctors will ask, Does this patient have the specific enzyme overactivity that this drug is designed to block?
“They are opening doors that we never would have been able to crack open,” Dr. Caleb Bupp, Corewell Health
The Rise of ‘N-of-1’ Trials and Regulatory Flexibility
Traditional large-scale clinical trials are nearly impossible for ultra-rare diseases. BABS, for example, has only about 20 diagnosed patients worldwide. When the patient pool is this minor, the gold standard of a double-blind, placebo-controlled trial becomes a mathematical impossibility.
To solve this, regulatory bodies like the U.S. Food and Drug Administration (FDA) are increasingly utilizing single-patient investigational protocols. This allows doctors to request access to a drug for a single individual based on the biological plausibility of the treatment.
We are likely heading toward a future where real-world evidence
(RWE)—data collected from actual clinical practice—carries as much weight as traditional trials for orphan drugs. This shift ensures that rarity does not equal a lack of treatment.
If you are navigating a rare diagnosis, appear for “Patient Advocacy Groups” and nonprofit biotech organizations like Every Cure. These organizations often bridge the gap between academic research and regulatory approval, providing resources that traditional hospitals may not have.
Collaborative Ecosystems: Nonprofits and Universities Joining Forces
The path to treating BABS was accelerated by a unique partnership between Corewell Health, the Michigan State University (MSU) College of Human Medicine, and Every Cure, a nonprofit biotech group. This ecosystem represents a new model for medical research.
By removing the profit motive associated with developing drugs for tiny patient populations, nonprofits can focus on the “valley of death”—the gap between a promising lab discovery and a usable treatment. This collaborative model is expected to expand, creating a global network where data on rare mutations is shared instantaneously across borders.
As genomic sequencing becomes cheaper and more accessible, the identification of these “hidden” patients will increase, providing the data necessary to turn experimental successes into standardized care.
Frequently Asked Questions
What is an orphan drug?
An orphan drug is a medication developed specifically to treat a rare medical condition. Because the market is small, governments often provide incentives to pharmaceutical companies to develop them.
Can any aged drug be repurposed?
No. Repurposing requires a match between the drug’s known mechanism (what it does to the body) and the disease’s biology (what is going wrong in the body). In BABS, the drug’s ability to block a specific enzyme matched the disease’s genetic overactivity.
How does a single-patient protocol work?
This proves a regulatory pathway that allows a physician to use an investigational drug for a single patient when no comparable alternative therapy exists and the potential benefit outweighs the risk.
Join the Conversation: Do you believe regulatory agencies should make it easier to access repurposed drugs for rare diseases, even without large-scale trials? Share your thoughts in the comments below or subscribe to our newsletter for more insights into the future of medicine.
